CT SB00197

Adds "biological product" (as defined in federal law 42 USC 262) to Connecticut pharmacy substitution laws, allowing pharmacists to substitute interchangeable biological products for prescribed ones unless the prescriber specifies "no substitution" (effective October 1, 2018).

Defines "interchangeable biological product" as one licensed by the FDA as interchangeable or therapeutically equivalent per FDA's official drug publications.

Requires pharmacists to inform patients and prescribers of biological product substitutions within 72 hours and document the specific product dispensed (including manufacturer) in the patient record within 48 hours.

Requires prescribers to discuss biological product treatment methods, alternatives, and risks with patients before prescribing and document the conversation in the medical record within 24 hours; patients may request to sign for delivery of interchangeable biological products.

Maintains existing pharmacy posting and consent requirements, and prohibits substitutions for epilepsy/seizure medications without prescriber written consent obtained via electronic mail or facsimile.